Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting

Sara Stafford (), Peter G. Bech, Adam Fridhammar, Nino Miresashvili, Andreas Nilsson, Michael Willis and Aiden Liu
Additional contact information
Sara Stafford: Fraser Health Division of Endocrinology
Peter G. Bech: Novo Nordisk Canada Inc.
Adam Fridhammar: The Swedish Institute for Health Economics
Nino Miresashvili: Novo Nordisk A/S
Andreas Nilsson: The Swedish Institute for Health Economics
Michael Willis: The Swedish Institute for Health Economics
Aiden Liu: Novo Nordisk Canada Inc.

Applied Health Economics and Health Policy, 2022, vol. 20, issue 4, No 14, 623-623

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-022-00734-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:20:y:2022:i:4:d:10.1007_s40258-022-00734-z

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-022-00734-z

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().